Reduced basal mTOR activity has also been observed in diverse models of lysosomal diseases including Neuronal Ceroid Lipofuscinosis type 3 lymphoblastoid cells [30], in NPC1- and NPC2-knockdown endothelial cells [16], in a Drosophila model of mucolipidosis IV [31], and a human podocyte model of Fabry disease [32]. This evidence concerns the gene MTOR and Lysosomal disease.